Strategies for non-viral vectors targeting organs beyond the liver
Source abstract
Abstract
In recent years, nanoparticles have evolved to a clinical modality to deliver diverse nucleic acids. Rising interest in nanomedicines comes from proven safety and efficacy profiles established by continuous efforts to optimize physicochemical properties and endosomal escape. However, despite their transformative impact on the pharmaceutical industry, the clinical use of non-viral nucleic acid delivery is limited to hepatic diseases and vaccines due to liver accumulation. Overcoming liver tropism of nanoparticles is vital to meet clinical needs in other organs. Understanding the anatomical structure and physiological features of various organs would help to identify potential strategies for fine-tuning nanoparticle characteristics. In this Review, we discuss the source of liver tropism of non-viral vectors, present a brief overview of biological structure, processes and barriers in select organs, highlight approaches available to reach non-liver targets, and discuss techniques to accelerate the discovery of non-hepatic therapies.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Zhang, Y.-N., Poon, W., Tavares, A. J., McGilvray, I. D. & Chan, W. C. W. Nanoparticle–liver interactions: cellular uptake and hepatobiliary elimination. J. Control. Release 240, 332–348 (2016).
2. Akinc, A. et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat. Nanotechnol. 14, 1084–1087 (2019).10.1038/s41565-019-0591-y ↗
3. Gillmore, J. D. et al. CRISPR–Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 385, 493–502 (2021).10.1056/NEJMoa2107454 ↗
4. Rotolo, L. et al. Species-agnostic polymeric formulations for inhalable messenger RNA delivery to the lung. Nat. Mater. 22, 369–379 (2023).10.1038/s41563-022-01404-0 ↗
5. Zhong, R. et al. Hydrogels for RNA delivery. Nat. Mater. 22, 818–831 (2023).10.1038/s41563-023-01472-w ↗
6. Van Haasteren, J. et al. The delivery challenge: fulfilling the promise of therapeutic genome editing. Nat. Biotechnol. 38, 845–855 (2020).10.1038/s41587-020-0565-5 ↗
7. Poon, W., Kingston, B. R., Ouyang, B., Ngo, W. & Chan, W. C. W. A framework for designing delivery systems. Nat. Nanotechnol. 15, 819–829 (2020). This Review thoroughly discusses the characteristics of NPs required for effective delivery within a biological context.10.1038/s41565-020-0759-5 ↗
8. Patel, S. et al. Brief update on endocytosis of nanomedicines. Adv. Drug Deliv. Rev. 144, 90–111 (2019).10.1016/j.addr.2019.08.004 ↗
9. Alameh, M.-G. et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 54, 2877–2892.e7 (2021).10.1016/j.immuni.2021.11.001 ↗
10. Han, X. et al. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines. Nat. Nanotechnol. 18, 1105–1114 (2023).10.1038/s41565-023-01404-4 ↗
11. Tsoi, K. M. et al. Mechanism of hard-nanomaterial clearance by the liver. Nat. Mater. 15, 1212–1221 (2016).10.1038/nmat4718 ↗
12. Klibanov, A. L., Maruyama, K., Torchilin, V. P. & Huang, L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268, 235–237 (1990).10.1016/0014-5793(90)81016-H ↗
13. Witzigmann, D. et al. Lipid nanoparticle technology for therapeutic gene regulation in the liver. Adv. Drug Deliv. Rev. 159, 344–363 (2020).10.1016/j.addr.2020.06.026 ↗
14. Akinc, A. et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357–1364 (2010). This study discovered that the ApoE–LDLR pathway facilitates hepatocyte transfection when LNPs contain ionizable cationic lipids but not when permanently cationic lipids are used.10.1038/mt.2010.85 ↗
15. Nair, J. K. et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136, 16958–16961 (2014).10.1021/ja505986a ↗
16. Kasiewicz, L. N. et al. GalNAc–lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy. Nat. Commun. 14, 2776 (2023).10.1038/s41467-023-37465-1 ↗
17. Ozelo, M. C. et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N. Engl. J. Med. 386, 1013–1025 (2022).10.1056/NEJMoa2113708 ↗
18. Sato, Y. et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat. Biotechnol. 26, 431–442 (2008).10.1038/nbt1396 ↗
19. Lawitz, E. J. et al. BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial. Hepatology 75, 912–923 (2022).10.1002/hep.32181 ↗
20. Han, X. et al. Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis. Nat. Commun. 14, 75 (2023).
21. Paunovska, K. et al. Nanoparticles containing oxidized cholesterol deliver mrna to the liver microenvironment at clinically relevant doses. Adv. Mater. 31, 1807748 (2019).10.1002/adma.201807748 ↗
22. Eygeris, Y., Gupta, M., Kim, J. & Sahay, G. Chemistry of lipid nanoparticles for RNA delivery. Acc. Chem. Res. 55, 2–12 (2022).10.1021/acs.accounts.1c00544 ↗
23. Zhang, Y., Sun, C., Wang, C., Jankovic, K. E. & Dong, Y. Lipids and lipid derivatives for RNA delivery. Chem. Rev. 121, 12181–12277 (2021).10.1021/acs.chemrev.1c00244 ↗
24. Viger-Gravel, J. et al. Structure of lipid nanoparticles containing sirna or mrna by dynamic nuclear polarization-enhanced NMR spectroscopy. J. Phys. Chem. B 122, 2073–2081 (2018).10.1021/acs.jpcb.7b10795 ↗
25. Goula, D. et al. Polyethylenimine-based intravenous delivery of transgenes to mouse lung. Gene Ther. 5, 1291–1295 (1998).
26. Green, J. J., Langer, R. & Anderson, D. G. A combinatorial polymer library approach yields insight into nonviral gene delivery. Acc. Chem. Res. 41, 749–759 (2008).10.1021/ar7002336 ↗
27. Joubert, F. et al. Precise and systematic end group chemistry modifications on PAMAM and poly(l-lysine) dendrimers to improve cytosolic delivery of mRNA. J. Control. Release 356, 580–594 (2023).
28. Yang, W., Mixich, L., Boonstra, E. & Cabral, H. Polymer-based mRNA delivery strategies for advanced therapies. Adv. Healthc. Mater. 12, 2202688 (2023).10.1002/adhm.202202688 ↗
29. Cabral, H., Miyata, K., Osada, K. & Kataoka, K. Block copolymer micelles in nanomedicine applications. Chem. Rev. 118, 6844–6892 (2018).10.1021/acs.chemrev.8b00199 ↗
30. He, D. & Wagner, E. Defined polymeric materials for gene delivery. Macromol. Biosci. 15, 600–612 (2015).10.1002/mabi.201400524 ↗
31. Reinhard, S. & Wagner, E. How to tackle the challenge of siRNA delivery with sequence-defined oligoamino amides. Macromol. Biosci. 17, 1600152 (2017).10.1002/mabi.201600152 ↗
32. DeSimone, J. M. Co-opting Moore’s law: therapeutics, vaccines and interfacially active particles manufactured via PRINT®. J. Control. Release 240, 541–543 (2016).
33. Patel, A. K. et al. Inhaled nanoformulated mRNA polyplexes for protein production in lung epithelium. Adv. Mater. 31, 1805116 (2019). This study explored the application of polymeric NPs for inhaled mRNA delivery, highlighting the potential advantage of polymers for nebulization through their self-assembly.10.1002/adma.201805116 ↗
34. Kalra, H. et al. Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLoS Biol. 10, e1001450 (2012).10.1371/journal.pbio.1001450 ↗
35. Wahlgren, J. et al. Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res. 40, e130–e130 (2012).10.1093/nar/gks463 ↗
36. Alvarez-Erviti, L. et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29, 341–345 (2011).10.1038/nbt.1807 ↗
37. Ståhl, A. et al. A novel mechanism of bacterial toxin transfer within host blood cell-derived microvesicles. PLoS Pathog. 11, e1004619 (2015).10.1371/journal.ppat.1004619 ↗
38. Melamed, J. R. et al. Ionizable lipid nanoparticles deliver mRNA to pancreatic β cells via macrophage-mediated gene transfer. Sci. Adv. 9, eade1444 (2023).10.1126/sciadv.ade1444 ↗
39. Wang, Q. et al. ARMMs as a versatile platform for intracellular delivery of macromolecules. Nat. Commun. 9, 960 (2018).
40. Segel, M. et al. Mammalian retrovirus-like protein PEG10 packages its own mRNA and can be pseudotyped for mRNA delivery. Science 373, 882–889 (2021).10.1126/science.abg6155 ↗
41. Elsharkasy, O. M. et al. Extracellular vesicles as drug delivery systems: why and how? Adv. Drug Deliv. Rev. 159, 332–343 (2020).10.1016/j.addr.2020.04.004 ↗
42. Klein, D. et al. Centyrin ligands for extrahepatic delivery of siRNA. Mol. Ther. 29, 2053–2066 (2021).10.1016/j.ymthe.2021.02.015 ↗
43. Brown, K. M. et al. Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates. Nat. Biotechnol. 40, 1500–1508 (2022).10.1038/s41587-022-01334-x ↗
44. Wels, M., Roels, D., Raemdonck, K., De Smedt, S. C. & Sauvage, F. Challenges and strategies for the delivery of biologics to the cornea. J. Control. Release 333, 560–578 (2021).
45. Baran-Rachwalska, P. et al. Topical siRNA delivery to the cornea and anterior eye by hybrid silicon-lipid nanoparticles. J. Control. Release 326, 192–202 (2020).
46. Bogaert, B. et al. A lipid nanoparticle platform for mRNA delivery through repurposing of cationic amphiphilic drugs. J. Control. Release 350, 256–270 (2022).
47. Kim, H. M. & Woo, S. J. Ocular drug delivery to the retina: current innovations and future perspectives. Pharmaceutics 13, 108 (2021).10.3390/pharmaceutics13010108 ↗
48. Yiu, G. et al. Suprachoroidal and subretinal injections of AAV using transscleral microneedles for retinal gene delivery in nonhuman primates. Mol. Ther. Methods Clin. Dev. 16, 179–191 (2020).10.1016/j.omtm.2020.01.002 ↗
49. Weng, C. Y. Bilateral subretinal voretigene neparvovec-rzyl (Luxturna) gene therapy. Ophthalmol. Retin. 3, 450 (2019).10.1016/j.oret.2019.02.007 ↗
50. Jaskolka, M. C. et al. Exploratory safety profile of EDIT-101, a first-in-human in vivo CRISPR gene editing therapy for CEP290-related retinal degeneration. Invest. Ophthalmol. Vis. Sci. 63, 2836–A0352 (2022).
51. Chirco, K. R., Martinez, C. & Lamba, D. A. Advancements in pre-clinical development of gene editing-based therapies to treat inherited retinal diseases. Vis. Res. 209, 108257 (2023).10.1016/j.visres.2023.108257 ↗
52. Leroy, B. P. et al. Efficacy and safety of sepofarsen, an intravitreal RNA antisense oligonucleotide, for the treatment of CEP290-associated Leber congenital amaurosis (LCA10): a randomized, double-masked, sham-controlled, phase 3 study (ILLUMINATE). Invest. Ophthalmol. Vis. Sci. 63, 4536-F0323 (2022).
53. Ammar, M. J., Hsu, J., Chiang, A., Ho, A. C. & Regillo, C. D. Age-related macular degeneration therapy: a review. Curr. Opin. Ophthalmol. 31, 215–221 (2020).10.1097/ICU.0000000000000657 ↗
54. Goldberg, R. et al. Efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA): 12-month results from the phase 3 OAKS and DERBY studies. Invest. Ophthalmol. Vis. Sci. 63, 1500–1500 (2022).
55. Shen, J. et al. Suprachoroidal gene transfer with nonviral nanoparticles. Sci. Adv. 6, eaba1606 (2020).10.1126/sciadv.aba1606 ↗
56. Tan, G. et al. A core-shell nanoplatform as a nonviral vector for targeted delivery of genes to the retina. Acta Biomater. 134, 605–620 (2021).10.1016/j.actbio.2021.07.053 ↗
57. Jin, J. et al. Anti-inflammatory and antiangiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor. Investig. Opthalmol. Vis. Sci. 52, 6230 (2011).
58. Keenan, T. D. L., Cukras, C. A. & Chew, E. Y. Age-related macular degeneration: epidemiology and clinical aspects. Adv. Exp. Med. Biol. 1256, 1–31 (2021).10.1007/978-3-030-66014-7_1 ↗
59. Chen, G. et al. A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing. Nat. Nanotechnol. 14, 974–980 (2019).10.1038/s41565-019-0539-2 ↗
60. Mirjalili Mohanna, S. Z. et al. LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea. J. Control. Release 350, 401–413 (2022).
61. Patel, S., Ryals, R. C., Weller, K. K., Pennesi, M. E. & Sahay, G. Lipid nanoparticles for delivery of messenger RNA to the back of the eye. J. Control. Release 303, 91–100 (2019).
62. Sun, D. et al. Non-viral gene therapy for stargardt disease with ECO/pRHO-ABCA4 self-assembled nanoparticles. Mol. Ther. 28, 293–303 (2020).10.1016/j.ymthe.2019.09.010 ↗
63. Herrera-Barrera, M. et al. Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates. Sci. Adv. 9, eadd4623 (2023).10.1126/sciadv.add4623 ↗
64. Huertas, A. et al. Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases: highlights from basic research to therapy. Eur. Respir. J. 51, 1700745 (2018).10.1183/13993003.00745-2017 ↗
65. Hong, K.-H. et al. Genetic ablation of the Bmpr2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation 118, 722–730 (2008).10.1161/CIRCULATIONAHA.107.736801 ↗
66. Dahlman, J. E. et al. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat. Nanotechnol. 9, 648–655 (2014).10.1038/nnano.2014.84 ↗
67. Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing. Nat. Nanotechnol. 15, 313–320 (2020). This groundbreaking study found that incorporating differently charged (SORT) lipids into the conventional four-component LNPs shifts the location of mRNA transfection among the liver, spleen and lungs.10.1038/s41565-020-0669-6 ↗
68. Dilliard, S. A., Cheng, Q. & Siegwart, D. J. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc. Natl Acad. Sci. USA 118, e2109256118 (2021). This work thoroughly investigated the impact of SORT lipids added to LNPs on the formation of the biomolecular corona on the NP surface and its role in achieving organ-specific transfection.10.1073/pnas.2109256118 ↗
69. Kimura, S. & Harashima, H. On the mechanism of tissue-selective gene delivery by lipid nanoparticles. J. Control. Release https://doi.org/10.1016/j.jconrel.2023.03.052 (2023).10.1016/j.jconrel.2023.03.052 ↗
70. Qiu, M. et al. Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc. Natl Acad. Sci. USA 119, e2116271119 (2022).10.1073/pnas.2116271119 ↗
71. Kaczmarek, J. C. et al. Polymer–lipid nanoparticles for systemic delivery of mRNA to the lungs. Angew. Chem. Int. Ed. 55, 13808–13812 (2016).10.1002/anie.201608450 ↗
72. Shen, A. M. & Minko, T. Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery. J. Control. Release 326, 222–244 (2020).
73. Alton, E. W. F. W. et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir. Med. 3, 684–691 (2015).10.1016/S2213-2600(15)00245-3 ↗
74. Kim, J. et al. Engineering lipid nanoparticles for enhanced intracellular delivery of mRNA through inhalation. ACS Nano 16, 14792–14806 (2022).
75. Lokugamage, M. P. et al. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nat. Biomed. Eng. 5, 1059–1068 (2021).10.1038/s41551-021-00786-x ↗
76. Qiu, Y. et al. Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide. J. Control. Release 314, 102–115 (2019).
77. Popowski, K. D. et al. Inhalable dry powder mRNA vaccines based on extracellular vesicles. Matter 5, 2960–2974 (2022).10.1016/j.matt.2022.06.012 ↗
78. Telko, M. J. & Hickey, A. J. Dry powder inhaler formulation. Respir. Care 50, 1209 (2005).
79. Li, B. et al. Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing. Nat. Biotechnol. https://doi.org/10.1038/s41587-023-01679-x (2023).10.1038/s41587-023-01679-x ↗
80. Fahy, J. V. & Dickey, B. F. Airway mucus function and dysfunction. N. Engl. J. Med. 363, 2233–2247 (2010).10.1056/NEJMra0910061 ↗
81. Schneider, C. S. et al. Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation. Sci. Adv. 3, e1601556 (2017).10.1126/sciadv.1601556 ↗
82. Wang, J. et al. Pulmonary surfactant–biomimetic nanoparticles potentiate heterosubtypic influenza immunity. Science 367, eaau0810 (2020).10.1126/science.aau0810 ↗
83. Rock, J. R., Randell, S. H. & Hogan, B. L. M. Airway basal stem cells: a perspective on their roles in epithelial homeostasis and remodeling. Dis. Model. Mech. 3, 545–556 (2010).10.1242/dmm.006031 ↗
84. Getts, D. R. et al. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat. Biotechnol. 30, 1217–1224 (2012).10.1038/nbt.2434 ↗
85. Leuschner, F. et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat. Biotechnol. 29, 1005–1010 (2011).10.1038/nbt.1989 ↗
86. Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144–150 (2023).10.1038/s41586-023-06063-y ↗
87. Bevers, S. et al. mRNA–LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells. Mol. Ther. 30, 3078–3094 (2022).10.1016/j.ymthe.2022.07.007 ↗
88. Blanco, E., Shen, H. & Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33, 941–951 (2015).10.1038/nbt.3330 ↗
89. Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396–401 (2016).10.1038/nature18300 ↗
90. Liu, S. et al. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR–Cas gene editing. Nat. Mater. 20, 701–710 (2021).10.1038/s41563-020-00886-0 ↗
91. Fenton, O. S. et al. Synthesis and biological evaluation of ionizable lipid materials for the in vivo delivery of messenger RNA to B lymphocytes. Adv. Mater. 29, 1606944 (2017).10.1002/adma.201606944 ↗
92. Zhao, X. et al. Imidazole‐based synthetic lipidoids for in vivo mRNA delivery into primary T lymphocytes. Angew. Chem. Int. Ed. 59, 20083–20089 (2020).10.1002/anie.202008082 ↗
93. LoPresti, S. T., Arral, M. L., Chaudhary, N. & Whitehead, K. A. The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungs. J. Control. Release 345, 819–831 (2022).
94. McKinlay, C. J., Benner, N. L., Haabeth, O. A., Waymouth, R. M. & Wender, P. A. Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters. Proc. Natl Acad. Sci. USA 115, E5859–E5866 (2018).10.1073/pnas.1805358115 ↗
95. McKinlay, C. J. et al. Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals. Proc. Natl Acad. Sci. USA 114, E448–E456 (2017).10.1073/pnas.1614193114 ↗
96. Ben-Akiva, E. et al. Biodegradable lipophilic polymeric mRNA nanoparticles for ligand-free targeting of splenic dendritic cells for cancer vaccination. Proc. Natl Acad. Sci. USA 120, e2301606120 (2023).10.1073/pnas.2301606120 ↗
97. Tombácz, I. et al. Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA–LNPs. Mol. Ther. 29, 3293–3304 (2021).10.1016/j.ymthe.2021.06.004 ↗
98. Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91–96 (2022).10.1126/science.abm0594 ↗
99. Kim, J., Eygeris, Y., Gupta, M. & Sahay, G. Self-assembled mRNA vaccines. Adv. Drug Deliv. Rev. 170, 83–112 (2021).10.1016/j.addr.2020.12.014 ↗
100. Lindsay, K. E. et al. Visualization of early events in mRNA vaccine delivery in non-human primates via PET–CT and near-infrared imaging. Nat. Biomed. Eng. 3, 371–380 (2019). This pioneering study delved into the biodistribution of lipid-based mRNA vaccines after their intramuscular injection into non-human primates using a dual radionuclide–near-infrared probe.10.1038/s41551-019-0378-3 ↗